{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:22:32Z","timestamp":1779909752786,"version":"3.53.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,17]]},"DOI":"10.7759\/cureus.19673","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T19:58:20Z","timestamp":1637179100000},"source":"Crossref","is-referenced-by-count":2,"title":["Guillain-Barr\u00e9 Syndrome Following an Extended-Spectrum Beta-Lactamase Escherichia coli Urinary Tract Infection: A Case Report"],"prefix":"10.7759","author":[{"given":"Aaron","family":"Fischer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Avila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.46.6330","article-title":"Rapidly progressive Guillain-Barr\u00e9 syndrome following Escherichia coli infection","volume":"46","author":"Kono Y","year":"2007","unstructured":"Kono Y, Nishitarumizu K, Higashi T, Funakoshi K, Odaka M. Rapidly progressive Guillain-Barr\u00e9 syndrome following Escherichia coli infection. Intern Med. 2007, 46:589-91. 10.2169\/internalmedicine.46.6330","journal-title":"Intern Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2018.33.e29","article-title":"Recurrent Guillain-Barr\u00e9 syndrome following urinary tract infection by Escherichia coli","volume":"33","author":"Jo YS","year":"2018","unstructured":"Jo YS, Choi JY, Chung H, Kim Y, Na SJ. Recurrent Guillain-Barr\u00e9 syndrome following urinary tract infection by Escherichia coli. J Korean Med Sci. 2018, 33:e29. 10.3346\/jkms.2018.33.e29","journal-title":"J Korean Med Sci"},{"key":"ref3","unstructured":"Guillain-Barr\u00e9 Syndrome Fact Sheet. (2021). Accessed. 11\/16\/2021: https:\/\/www.ninds.nih.gov\/Disorders\/Patient-Caregiver-Education\/Fact-Sheets\/Guillain-Barr%C3%A9-Syndrome-Fact-Sheet."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199204233261706","article-title":"The Guillain-Barr\u00e9 syndrome","volume":"326","author":"Ropper AH","year":"1992","unstructured":"Ropper AH. The Guillain-Barr\u00e9 syndrome. N Engl J Med. 1992, 326:1130-6. 10.1056\/NEJM199204233261706","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2013.01.005","article-title":"Guillain-Barr\u00e9 syndrome and variants","volume":"31","author":"Dimachkie MM","year":"2013","unstructured":"Dimachkie MM, Barohn RJ. Guillain-Barr\u00e9 syndrome and variants. Neurol Clin. 2013, 31:491-510. 10.1016\/j.ncl.2013.01.005","journal-title":"Neurol Clin"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2013.05.001","article-title":"Glycolipid antigens and autoantibodies in autoimmune neuropathies","volume":"34","author":"Willison HJ","year":"2013","unstructured":"Willison HJ, Goodyear CS. Glycolipid antigens and autoantibodies in autoimmune neuropathies. Trends Immunol. 2013, 34:453-9. 10.1016\/j.it.2013.05.001","journal-title":"Trends Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1114525","article-title":"Guillain-Barr\u00e9 syndrome","volume":"366","author":"Yuki N","year":"2012","unstructured":"Yuki N, Hartung HP. Guillain-Barr\u00e9 syndrome. N Engl J Med. 2012, 366:2294-304. 10.1056\/NEJMra1114525","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70215-1","article-title":"Axonal Guillain-Barr\u00e9 syndrome: concepts and controversies","volume":"12","author":"Kuwabara S","year":"2013","unstructured":"Kuwabara S, Yuki N. Axonal Guillain-Barr\u00e9 syndrome: concepts and controversies. Lancet Neurol. 2013, 12:1180-8. 10.1016\/S1474-4422(13)70215-1","journal-title":"Lancet Neurol"},{"key":"ref9","unstructured":"Paraneoplastic Antibodies (Hu, Yo, Ri). (2011). Accessed. 04\/01\/2021: https:\/\/www.heftpathology.com\/item\/paraneoplastic-antibodies-hu-yo-ri.html?category_id=15."},{"key":"ref10","unstructured":"\u200b\ufeff\u200bParaneoplastic Antibodies (anti-Hu,Yo, Ri, Ma). Accessed. 04\/01\/2021: https:\/\/www.southtees.nhs.uk\/services\/pathology\/tests\/paraneoplastic-antibodies-anti-huyo-ri-ma\/."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002063.pub6","article-title":"Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome","author":"Hughes RA","year":"2014","unstructured":"Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome. Cochrane Database Syst Rev. 2014, CD002063. 10.1002\/14651858.CD002063.pub6","journal-title":"Cochrane Database Syst Rev"},{"key":"ref12","article-title":"Rehabilitation interventions in patients with acute demyelinating inflammatory polyneuropathy: a systematic review","volume":"48","author":"Khan F","year":"2012","unstructured":"Khan F, Amatya B. Rehabilitation interventions in patients with acute demyelinating inflammatory polyneuropathy: a systematic review.  Eur J Phys Rehab Med. 2012, 48: 507-22.","journal-title":"Eur J Phys Rehab Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.61.6.736","article-title":"Practice parameter: immunotherapy for Guillain-Barr\u00e9 syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"61","author":"Hughes RA","year":"2003","unstructured":"Hughes RA, Wijdicks EF, Barohn R, et al.. Practice parameter: immunotherapy for Guillain-Barr\u00e9 syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2003, 61:736-40. 10.1212\/wnl.61.6.736","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1159\/000354893","article-title":"Intravenous immunoglobulins: in-depth review of excipients and acute kidney injury risk","volume":"38","author":"Dantal J","year":"2013","unstructured":"Dantal J. Intravenous immunoglobulins: in-depth review of excipients and acute kidney injury risk. Am J Nephrol. 2013, 38:275-84. 10.1159\/000354893","journal-title":"Am J Nephrol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001446.pub2","article-title":"Corticosteroids for Guillain-Barr\u00e9 syndrome","author":"Hughes RA","year":"2006","unstructured":"Hughes RA, Swan AV, van Koningsveld R, van Doorn PA. Corticosteroids for Guillain-Barr\u00e9 syndrome. Cochrane Database Syst Rev. 2006, CD001446. 10.1002\/14651858.CD001446.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref16","article-title":"Multidisciplinary care for Guillain-Barr\u00e9 syndrome","volume":"10","author":"Khan F","year":"2010","unstructured":"Khan F, Ng L, Amatya B, Brand C, Turner-Stokes L. Multidisciplinary care for Guillain-Barr\u00e9 syndrome.  The Cochrane Database of Syst Rev. 2010, 10:CD008505. 1002\/14651858.CD008505.pub2","journal-title":"The Cochrane Database of Syst Rev"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/66789-guillain-barr-syndrome-following-an-extended-spectrum-beta-lactamase-escherichia-coli-urinary-tract-infection-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:30:48Z","timestamp":1707507048000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/66789-guillain-barr-syndrome-following-an-extended-spectrum-beta-lactamase-escherichia-coli-urinary-tract-infection-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,17]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.19673","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,17]]}}}